EUCTR2018-004505-34-NL进行中（未招募）1 期
A phase 2a study on the anti-tumoral effect of cannabis oil (THC 10% / CBD 5%) in patients with advanced untreatable hepatocellular carcinoma - Medicinal cannabisoil for untreatable HCC patients
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 20
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •- Age =>18 yrs
- •- Histologically proven hepatocellular carcinoma
- •- MDT-advised best supportive care for untreatable advanced HCC or patients unable to undergo or denying treatment for advanced HCC.
- •- Minimal life expectancy of 3 months
- •- Willing and able to attend follow-up examinations
- •- Willing to stop driving, if applicable
- •- Signed informed consent
- •- Language: Dutch or English
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 10
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 10
排除标准
- •-Mental conditions rendering the subject incapable to understand the nature, scope and consequences of the trial
- •-Contra-indications for medicinal cannabis oil:
- •oPsychotic disorders
- •oCardiac arrhythmias
- •oAngina pectoris
- •oPregnancy or lactation
研究者
相似试验
尚未招募
不适用
A phase 2a study on the anti-tumoral effect of cannabis oil (THC 10% / CBD 5%) in untreatable advanced hepatocellular carcinoma patientsHepatocellular carcinomaNL-OMON28248MCG20
招募中
2 期
A phase 2a study on the anti-tumoral effect of cannabis oil (THC 10% / CBD 5%) in patients with untreatable advanced hepatocellular carcinomahepatocellular carcinoma (liver cancer)10019815NL-OMON49322niversitair Medisch Centrum Groningen20
进行中（未招募）
不适用
A study of the effect of Liproca® Depot on prostate cancerEUCTR2011-001137-16-SEIDDS AB28
进行中（未招募）
不适用
A study of the effect of Liproca® Depot on prostate cancerocalized prostate cancerEUCTR2011-001137-16-FIIDDS AB18
已完成
不适用
Investigation of anti-tumoral effect and safety of combination therapy LD-GP (low dose gemcitabine and paclitaxel) therapy and sorafenib in patients with cisplatin-resistant advanced urothelial cancer.Cisplatin-resistant urothelial cancerJPRN-UMIN000010957agasaki University Hospital15